Literature DB >> 18585084

Strengths and limitations of genetic mouse models of Parkinson's disease.

Marie-Francoise Chesselet1, Sheila Fleming, Farzad Mortazavi, Bernd Meurers.   

Abstract

Genetic mouse models based on alpha-synuclein overexpression are particularly compelling because abnormal accumulation of alpha-synuclein occurs in sporadic Parkinson's disease (PD). Our laboratory has characterized a mouse overexpressing wild-type human alpha-synuclein under the Thy1 promoter, which confers broad expression of the transgene in neurons. These mice show progressive sensorimotor anomalies starting at 2 months of age, as well as olfactory and digestive deficits similar to those observed in patients at early stages of PD. Patterns of gene expression examined in nigrostriatal neurons isolated by single-cell laser capture microdissection in these mice at 6 months of age show an upregulation of defence mechanisms including increased levels of genes involved in proteasome and mitochondrial function, as well as cholesterol biosynthesis. At the same time, numerous alterations in genes encoding ion channels suggest that changes in the cellular function of these neurons occur independently of cell death. These data provide information on the early effects--in a mammalian brain--of a mutation known to cause PD, and they identify a number of useful end points for evaluating potential neuroprotective therapies that could interfere with the pathophysiological mechanisms of PD upstream of neuronal cell death.

Entities:  

Mesh:

Year:  2008        PMID: 18585084      PMCID: PMC2577895          DOI: 10.1016/j.parkreldis.2008.04.004

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  21 in total

1.  Staging of brain pathology related to sporadic Parkinson's disease.

Authors:  Heiko Braak; Kelly Del Tredici; Udo Rüb; Rob A I de Vos; Ernst N H Jansen Steur; Eva Braak
Journal:  Neurobiol Aging       Date:  2003 Mar-Apr       Impact factor: 4.673

2.  Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease.

Authors:  Anthony E Lang; José A Obeso
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

Review 3.  Basal ganglia and movement disorders: an update.

Authors:  M F Chesselet; J M Delfs
Journal:  Trends Neurosci       Date:  1996-10       Impact factor: 13.837

4.  Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons.

Authors:  U Ungerstedt; T Ljungberg; G Steg
Journal:  Adv Neurol       Date:  1974

5.  Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.

Authors:  Sheila M Fleming; Jonathan Salcedo; Pierre-Olivier Fernagut; Edward Rockenstein; Eliezer Masliah; Michael S Levine; Marie-Françoise Chesselet
Journal:  J Neurosci       Date:  2004-10-20       Impact factor: 6.167

Review 6.  Stages in the development of Parkinson's disease-related pathology.

Authors:  Heiko Braak; Estifanos Ghebremedhin; Udo Rüb; Hansjürgen Bratzke; Kelly Del Tredici
Journal:  Cell Tissue Res       Date:  2004-08-24       Impact factor: 5.249

Review 7.  The rotenone model of Parkinson's disease: genes, environment and mitochondria.

Authors:  J Timothy Greenamyre; Ranjita Betarbet; Todd B Sherer
Journal:  Parkinsonism Relat Disord       Date:  2003-08       Impact factor: 4.891

Review 8.  Alpha-synuclein and transgenic mouse models.

Authors:  Pierre-Olivier Fernagut; Marie-Françoise Chesselet
Journal:  Neurobiol Dis       Date:  2004-11       Impact factor: 5.996

Review 9.  In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?

Authors:  Marie-Francoise Chesselet
Journal:  Exp Neurol       Date:  2007-08-23       Impact factor: 5.330

10.  Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Authors:  Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

View more
  28 in total

1.  Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.

Authors:  A M Willard; R S Bouchard; A H Gittis
Journal:  Neuroscience       Date:  2015-06-09       Impact factor: 3.590

Review 2.  How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?

Authors:  Laura A Volpicelli-Daley; Deniz Kirik; Lindsay E Stoyka; David G Standaert; Ashley S Harms
Journal:  J Neurochem       Date:  2016-05-04       Impact factor: 5.372

Review 3.  Genetic animal models of Parkinson's disease.

Authors:  Ted M Dawson; Han Seok Ko; Valina L Dawson
Journal:  Neuron       Date:  2010-06-10       Impact factor: 17.173

4.  α-Synuclein overexpressing transgenic mice show internal organ pathology and autonomic deficits.

Authors:  Penelope J Hallett; Jesse R McLean; Andrew Kartunen; J William Langston; Ole Isacson
Journal:  Neurobiol Dis       Date:  2012-04-19       Impact factor: 5.996

Review 5.  Gene-environment interactions: key to unraveling the mystery of Parkinson's disease.

Authors:  Hui-Ming Gao; Jau-Shyong Hong
Journal:  Prog Neurobiol       Date:  2011-03-23       Impact factor: 11.685

Review 6.  Biologia Futura: the importance of 3D organoids-a new approach for research on neurological and rare diseases.

Authors:  Tayfun Hilmi Akbaba; Can Ebru Bekircan-Kurt; Banu Balci-Peynircioglu; Burcu Balci-Hayta
Journal:  Biol Futur       Date:  2021-02-10

7.  Effects of small-molecule amyloid modulators on a Drosophila model of Parkinson's disease.

Authors:  Małgorzata Pokrzywa; Katarzyna Pawełek; Weronika Elżbieta Kucia; Szymon Sarbak; Erik Chorell; Fredrik Almqvist; Pernilla Wittung-Stafshede
Journal:  PLoS One       Date:  2017-09-01       Impact factor: 3.240

Review 8.  The importance of molecular histology to study glial influence on neurodegenerative disorders. Focus on recent developed single cell laser microdissection.

Authors:  Gerson Chadi; Jessica Ruivo Maximino; Gabriela Pintar de Oliveira
Journal:  J Mol Histol       Date:  2009-11-01       Impact factor: 2.611

9.  Progressive dopaminergic degeneration in the chronic MPTPp mouse model of Parkinson's disease.

Authors:  Nicoletta Schintu; Lucia Frau; Marcello Ibba; Arianna Garau; Ezio Carboni; Anna R Carta
Journal:  Neurotox Res       Date:  2009-05-27       Impact factor: 3.911

10.  Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease.

Authors:  James B Koprich; Tom H Johnston; M Gabriela Reyes; Xuan Sun; Jonathan M Brotchie
Journal:  Mol Neurodegener       Date:  2010-10-28       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.